Obstructive Sleep ApneaOSASNCT01791270
Obstructive Sleep Apnea (OSA), Hypertension , β1 Subunit of Maxi-k+ Channel and Cardiovascular Risk
An observational study of Obstructive Sleep Apnea, run by Angeles Sanchez Armengol.
Trial summary
To describe the relationship between OSA and clinical Hypertension (performing ABPM), endothelial dysfunction (performing flowmetry), and its relation at the basic research (determining the β1 subunit in Peripheral Leukocytes in peripheral blood). Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Obstructive Sleep Apnea
- What is being tested?
- Continuous positive airway pressure (CPAP) therapy
- Type of treatment
- Medical device
- How many people
- 80 participants
- Where
- No sites listed yet
- Study dates
- Feb 2010to Dec 2012
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Group of OSA patients and a control group without OSA
Who may be able to join
- The control group was defined as "absence of OSA"(apnea-hypopnea index (AHI) in cardiorespiratory polygraphy <5).
- The "OSA" group was defined as OSA symptoms + an AHI ≥ 15 in cardiorespiratory polygraphy
Who cannot join
- Awaking hypoxemia (PO2 in arterial blood gas <70 mmHg) or arterial saturation <90% in digital pulse oximetry.
- Treated hypertensive patients who were not well controlled at the time of inclusion: change of HTA treatment in the previous 3 months.
About this study
Official title: Expression of Maxi-k+ Channel β1 Subunit in Peripheral Leukocytes, Blood Pressure Values and the Presence of Endothelial Dysfunction in Patients With Obstructive Sleep Apnea
To describe the relationship between OSA and clinical Hypertension (performing ABPM), endothelial dysfunction (performing flowmetry), and its relation at the basic research (determining the β1 subunit in Peripheral Leukocytes in peripheral blood). This relation between OSA and HTA has been evaluated in basal conditions and after modifying the pathophysiological role of OSA applying treatment with positive continues pressure (CPAP) during 3 months.
Read the detailed description
Background: Several epidemiological studies have demonstrated that untreated OSA with continuous positive airway pressure, is related to high rates of cardiovascular morbidity and mortality, being HTA the most important cardiovascular morbidity associated with OSA. This relationship has been studied at three levels: clinical, subclinical and the basic research or molecular level. Most patients with OSA diagnosis have developed clinical hypertension and, because of the high prevalence of nocturnal hypertension in OSA, it would be essential to monitor blood pressure during sleep, using this device ambulatory blood pressure monitoring (ABPM). Regard to endothelial dysfunction, which can exist before irreversible vascular changes have occurred in the arterial wall (subclinical level) has been reported that patients with OSA have lower blood flow (measured by arterial flowmetry) and after treatment with CPAP, there is an improvement in endothelial function. At basic research level, in previous studies it has been observed that hypoxia down regulates the expression of Maxi-K+ Channel B1-subunit in smooth muscle cell and also in peripheral leukocytes. This channel is involved in the regulation of arterial vasodilation, being β1 subunit responsible for the vascular tone regulation. Basic research studies have shown the relationship between hypertension and ß1 subunit, describing that the expression of that unit decreases in hypertensive animal models. In a pilot study in OSA patients was suggested that ß1 subunit channel Maxi-K + could play an important role in vascular dysregulation of these patients. It has been also described a correlation between ß1 subunit level in vascular smooth muscle cells and its level in leukocytes.
Objective: To describe the relationship between OSA and hypertension from a clinical point of view (by performing ABPM), its relationship with endothelial dysfunction (by performing a flowmetry) and basic research level (by the determination of β1 subunit of the maxi-K channel +). This relationship between hypertension and OSA has been assessed at baseline condition in a group of OSA patients and a control group without OSA, and after changing the pathophysiological role of OSA treating with continuous positive pressure airway (CPAP) in the group of OSA patients.
Patients: Prospective study in which:
- - We compared 61 patients with sleep apnea-hypopnea syndrome and 19 control subjects without OSA.
- - In the group of 61 patients with OSA: we compared the results before and after three months of correct treatment with CPAP.
Measurements:
- - Respiratory Polygraphy
- - Ambulatory Blood Pressure Monitoring
- - Endothelial dysfunction, by determining the hyperaemic response to ischemia using a Laser-Doppler flowmeter.
- - ß1en subunit expression in peripheral blood leukocytes.
These procedures are described below:
- - Respiratory Polygraphy: -Nocturnal cardiorespiratory polygraphy was performed in the "sleep laboratory of Medical-Surgical Unit of Respiratory Diseases". It has used a respiratory polygraph "Sibelhome plus"(trade name). We measured the following variables:
- Oronasal Flow.
- Snore: using laryngotracheal microphone.
- Thoracoabdominal-Effort: by two bands effort sensors placed at the level of the chest and abdomen.
- Arterial oxygen saturation (SaO2): Flexible digital pulse oximeter.
- Body-position sensor. The records are stored in a specific database and analysis was carried out manually. The events are defined
- Apnea: absence of oronasal airflow for ≥ 10 sec.
- Hypopnea: oronasal flow decrease ≥ 50% from baseline for ≥ 10 seconds, accompanied by desaturation. We calculated the following parameters:
- AHI: total number of apnea + hypopnea / hour check. When AHI is <5 was considered negative for OSA and when AHI WAS ≥ 15, OSA diagnosis was made.
- Desaturation index (DI): total number of desaturations / hour check.
- Basal and minimum-Saturation: automatic analysis obtained oximetry throughout the entire record.
- Percentage of recording time with SaO2 <90% (CT90): automatic analysis obtained oximetry throughout the entire record.
- - Ambulatory Blood Pressure Monitoring: The dispositive measures blood pressure automatically every 20 minutes for 24 hours. The records were obtained on a weekday and when the patient worked in shifts, it was made when the patients didn´t work at night. We collected the following variables:
- 24hours systolic and diastolic blood pressure.
- Medium blood pressure at day and night.
- Standard deviation day and night blood pressure.
- Percentage of high measured for 24 hours, and during periods of activity and rest.
- BP variability (standard deviation of the mean).
- 24-hour mean heart rate.
- Average heart rate daytime.
- Night Average heart rate.
- - Endothelial dysfunction, by determining the hyperaemic response to ischemia using a Laser-Doppler flowmeter: The subject lay on the bed, and kept quiet 15-20 minutes. A cuff blood pressure measurement (uninflated) was placed on the arm and laser-Doppler device in the forearm. During 15 minutes the system measured basal situation and after that the cuff rapidly swelled over 20mmHg of the systolic blood pressure during for 4 minutes. During this period the system monitor showed perfusion units and at the end of this period the cuff was suddenly deflated and the monitor revealed a rise above the pre-ischemia in perfusion units. The software performed two types of analysis:
- General analysis: where reported the initial value, maximum value, percentage change from the first to last value or maximum slope of the curve or slope and area under the curve.
- Adjusted Analysis: It was estimated biological zero, peak flow, hyperemia area, time to maximum hyperemia, time to reach the half-maximal hyperemia and latency.
- - ß1 subunit expression in peripheral blood leukocytes: Performing the level of β1 subunit of Maxi-K + channel expression in peripheral blood leukocytes. Extraction total RNA from leukocytes following the instructions QIAamp RNA Blood Mini kit.
From these cells was performed the expression level of β1 subunit by quantitative RT-PCR technique. For reverse transcription of RNA using the Superscript III First-kit Starnd Synthesis System (trade name). For quantitative PCR we used the ABI PRISM equipment 7500 Sequence Detection System (Applied Biosystems), using the reagents Sybr Green PCR Master Mix or TaqMan probes, following the protocols indicated by the manufacturer.
- Conditions
- Obstructive Sleep Apnea
- Being tested
- Continuous positive airway pressure (CPAP) therapy
- Keywords
- Obstructive Sleep Apnea, Hypertension, β1 Subunit of Maxi-k+Channel, Cardiovascular Risk
- Medical subject headings
- Sleep Apnea, Obstructive, Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Continuous positive airway pressure (CPAP) therapyDevice
Device: CPAP accordingly to the normal therapy in daily practice. In the group of 61 patients with OSA: we compared the results before and after three months of correct treatment with CPAP.
First, an automatic continuous positive airway pressure device (autoCPAP REMstar) was used to evaluate the pressure titration by night registration at patient home. AutoCPAP gets complete information about the optimum level to be set as therapeutic (CPAP pressure).
The patient has been reevaluated periodically in the outpatient Sleep Unit to verify proper adaptation and compliance of CPAP.
We considered a proper compliance when patients used CPAP ≥ 4 hours/day. This data has been extracted from the counter included in the CPAP compressor.
Procedures:
- - Respiratory Polygraphy
- - Ambulatory Blood Pressure Monitoring
- - Endothelial dysfunction, by determining the hyperaemic response to ischemia using a Laser-Doppler flowmeter.
- - ß1en subunit expression in peripheral blood leukocytes.
| Study group | Role | What they receive |
|---|---|---|
| OSA versus Control subjects. | sleep apnea-hypopnea syndrome and control | |
| OSA patients before and after treatment, CPAP | Continuous positive pressure CPAP Receives: Device: Continuous positive airway pressure (CPAP) therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Improvement in blood pressure parameters, in vascular endothelial function and in levels of β1 subunit expression of Maxi-K + channel in patients with OSA after treatment with CPAP
Primary Outcome Measure: Look at the difference in OSA and control subjects between the parameters that measure blood pressure in AMBP, the reactive hyperemia test for ischemia flowmetry technique and the expression levels of ß1 subunit of the Maxi-K + channel in peripheral blood leukocytes.
In OSA group patients after three months of correct treatment with CPAP, the goal is to find:
- Improvement in blood pressure parameters (ambulatory blood pressure).
- Improved parameters expressing vascular endothelial function at subclinical level (recorded by laser-Doppler flowmetry).
- Improvement in levels of β1 subunit expression of Maxi-K + channel in peripheral blood leukocytes (basic).
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Feb 2013 (estimated)
- Study startFeb 2010
- Primary completionDec 2011
- Study completionDec 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Obstructive Sleep ApneaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Angeles Sanchez Armengol
- Sponsor type
- University, hospital or other
- Collaborators
- Junta de Andalucia
- Responsible party
- Sponsor-investigator, Angeles Sanchez Armengol, Sociedad Española de Neumología y Cirugía Torácica
- Investigators
- Angeles Sánchez Armengol, Md PhD, Principal investigator, Hospitales Universitarios Virgen del Rocío
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01791270
- Sponsor's protocol ID
- P09-CTS-4971
- Acronym
- OSAS
- Status last verified
- Jun 2013
- First submitted
- 12 Feb 2013
- Last updated
- 21 Jun 2013
- Results posted
- No
- Data monitoring committee
- No
Publications
Caballero-Eraso C, Munoz-Hernandez R, Asensio Cruz MI, Moreno Luna R, Carmona Bernal C, Lopez-Campos JL, Stiefel P, Sanchez Armengol A. Relationship between the endothelial dysfunction and the expression of the beta1-subunit of BK channels in a non-hypertensive sleep apnea group. PLoS One. 2019 Jun 19;14(6):e0217138. doi: 10.1371/journal.pone.0217138. eCollection 2019.
PubMed 31216297
Study at a glance
From the registry record, last updated by the sponsor on 21 Jun 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Expression of Maxi-k+ Channel β1 Subunit in Peripheral Leukocytes, Blood Pressure Values and the Presence of Endothelial Dysfunction in Patients With Obstructive Sleep Apnea
- ClinicalTrials.gov ID
- NCT01791270
- Acronym / sponsor ID
- OSAS / P09-CTS-4971
- Conditions
- Obstructive Sleep Apnea
- Keywords
- Obstructive Sleep Apnea, Hypertension, β1 Subunit of Maxi-k+Channel, Cardiovascular Risk
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Angeles Sanchez ArmengolUniversity, hospital or other
- Collaborators
- Junta de Andalucia
- Study start
- Feb 2010
- Primary completion
- Dec 2011 (actual)
- Study completion
- Dec 2012 (actual)
- First posted
- 13 Feb 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To describe the relationship between OSA and clinical Hypertension (performing ABPM), endothelial dysfunction (performing flowmetry), and its relation at the basic research (determining the β1 subunit in Peripheral Leukocytes in peripheral blood). This relation between OSA and HTA has been evaluated in basal conditions and after modifying the pathophysiological role of OSA applying treatment with positive continues pressure (CPAP) during 3 months.
Detailed description
Background: Several epidemiological studies have demonstrated that untreated OSA with continuous positive airway pressure, is related to high rates of cardiovascular morbidity and mortality, being HTA the most important cardiovascular morbidity associated with OSA. This relationship has been studied at three levels: clinical, subclinical and the basic research or molecular level. Most patients with OSA diagnosis have developed clinical hypertension and, because of the high prevalence of nocturnal hypertension in OSA, it would be essential to monitor blood pressure during sleep, using this device ambulatory blood pressure monitoring (ABPM). Regard to endothelial dysfunction, which can exist before irreversible vascular changes have occurred in the arterial wall (subclinical level) has been reported that patients with OSA have lower blood flow (measured by arterial flowmetry) and after treatment with CPAP, there is an improvement in endothelial function. At basic research level, in previous studies it has been observed that hypoxia down regulates the expression of Maxi-K+ Channel B1-subunit in smooth muscle cell and also in peripheral leukocytes. This channel is involved in the regulation of arterial vasodilation, being β1 subunit responsible for the vascular tone regulation. Basic research studies have shown the relationship between hypertension and ß1 subunit, describing that the expression of that unit decreases in hypertensive animal models. In a pilot study in OSA patients was suggested that ß1 subunit channel Maxi-K + could play an important role in vascular dysregulation of these patients. It has been also described a correlation between ß1 subunit level in vascular smooth muscle cells and its level in leukocytes.
Objective: To describe the relationship between OSA and hypertension from a clinical point of view (by performing ABPM), its relationship with endothelial dysfunction (by performing a flowmetry) and basic research level (by the determination of β1 subunit of the maxi-K channel +). This relationship between hypertension and OSA has been assessed at baseline condition in a group of OSA patients and a control group without OSA, and after changing the pathophysiological role of OSA treating with continuous positive pressure airway (CPAP) in the group of OSA patients.
Patients: Prospective study in which:
- - We compared 61 patients with sleep apnea-hypopnea syndrome and 19 control subjects without OSA.
- - In the group of 61 patients with OSA: we compared the results before and after three months of correct treatment with CPAP.
Measurements:
- - Respiratory Polygraphy
- - Ambulatory Blood Pressure Monitoring
- - Endothelial dysfunction, by determining the hyperaemic response to ischemia using a Laser-Doppler flowmeter.
- - ß1en subunit expression in peripheral blood leukocytes.
These procedures are described below:
- - Respiratory Polygraphy: -Nocturnal cardiorespiratory polygraphy was performed in the "sleep laboratory of Medical-Surgical Unit of Respiratory Diseases". It has used a respiratory polygraph "Sibelhome plus"(trade name). We measured the following variables:
- Oronasal Flow.
- Snore: using laryngotracheal microphone.
- Thoracoabdominal-Effort: by two bands effort sensors placed at the level of the chest and abdomen.
- Arterial oxygen saturation (SaO2): Flexible digital pulse oximeter.
- Body-position sensor. The records are stored in a specific database and analysis was carried out manually. The events are defined
- Apnea: absence of oronasal airflow for ≥ 10 sec.
- Hypopnea: oronasal flow decrease ≥ 50% from baseline for ≥ 10 seconds, accompanied by desaturation. We calculated the following parameters:
- AHI: total number of apnea + hypopnea / hour check. When AHI is <5 was considered negative for OSA and when AHI WAS ≥ 15, OSA diagnosis was made.
- Desaturation index (DI): total number of desaturations / hour check.
- Basal and minimum-Saturation: automatic analysis obtained oximetry throughout the entire record.
- Percentage of recording time with SaO2 <90% (CT90): automatic analysis obtained oximetry throughout the entire record.
- - Ambulatory Blood Pressure Monitoring: The dispositive measures blood pressure automatically every 20 minutes for 24 hours. The records were obtained on a weekday and when the patient worked in shifts, it was made when the patients didn´t work at night. We collected the following variables:
- 24hours systolic and diastolic blood pressure.
- Medium blood pressure at day and night.
- Standard deviation day and night blood pressure.
- Percentage of high measured for 24 hours, and during periods of activity and rest.
- BP variability (standard deviation of the mean).
- 24-hour mean heart rate.
- Average heart rate daytime.
- Night Average heart rate.
- - Endothelial dysfunction, by determining the hyperaemic response to ischemia using a Laser-Doppler flowmeter: The subject lay on the bed, and kept quiet 15-20 minutes. A cuff blood pressure measurement (uninflated) was placed on the arm and laser-Doppler device in the forearm. During 15 minutes the system measured basal situation and after that the cuff rapidly swelled over 20mmHg of the systolic blood pressure during for 4 minutes. During this period the system monitor showed perfusion units and at the end of this period the cuff was suddenly deflated and the monitor revealed a rise above the pre-ischemia in perfusion units. The software performed two types of analysis:
- General analysis: where reported the initial value, maximum value, percentage change from the first to last value or maximum slope of the curve or slope and area under the curve.
- Adjusted Analysis: It was estimated biological zero, peak flow, hyperemia area, time to maximum hyperemia, time to reach the half-maximal hyperemia and latency.
- - ß1 subunit expression in peripheral blood leukocytes: Performing the level of β1 subunit of Maxi-K + channel expression in peripheral blood leukocytes. Extraction total RNA from leukocytes following the instructions QIAamp RNA Blood Mini kit.
From these cells was performed the expression level of β1 subunit by quantitative RT-PCR technique. For reverse transcription of RNA using the Superscript III First-kit Starnd Synthesis System (trade name). For quantitative PCR we used the ABI PRISM equipment 7500 Sequence Detection System (Applied Biosystems), using the reagents Sybr Green PCR Master Mix or TaqMan probes, following the protocols indicated by the manufacturer.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| OSA versus Control subjects. | – | –sleep apnea-hypopnea syndrome and control |
| OSA patients before and after treatment, CPAP | – | Device: Continuous positive airway pressure (CPAP) therapyContinuous positive pressure CPAP |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Group of OSA patients and a control group without OSA
Key inclusion criteria (2 listed)
- The control group was defined as "absence of OSA"(apnea-hypopnea index (AHI) in cardiorespiratory polygraphy <5).
- The "OSA" group was defined as OSA symptoms + an AHI ≥ 15 in cardiorespiratory polygraphy
Key exclusion criteria (2 listed)
- Awaking hypoxemia (PO2 in arterial blood gas <70 mmHg) or arterial saturation <90% in digital pulse oximetry.
- Treated hypertensive patients who were not well controlled at the time of inclusion: change of HTA treatment in the previous 3 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Continuous positive airway pressure (CPAP) therapyDevice: CPAP accordingly to the normal therapy in daily practice. In the group of 61 patients with OSA: we compared the results before and after three months of correct treatment with CPAP. First, an automatic continuous positive airway pressure device (autoCPAP REMstar) was used to evaluate the pressure titration by night registration at patient home. AutoCPAP gets complete information about the optimum level to be set as therapeutic (CPAP pressure). The patient has been reevaluated periodically in the outpatient Sleep Unit to verify proper adaptation and compliance of CPAP. We considered a proper compliance when patients used CPAP ≥ 4 hours/day. This data has been extracted from the counter included in the CPAP compressor. Procedures: 1. - Respiratory Polygraphy 2. - Ambulatory Blood Pressure Monitoring 3. - Endothelial dysfunction, by determining the hyperaemic response to ischemia using a Laser-Doppler flowmeter. 4. - ß1en subunit expression in peripheral blood leukocytes. | Device | OSA patients before and after treatment, CPAP |
Primary outcome
Improvement in blood pressure parameters, in vascular endothelial function and in levels of β1 subunit expression of Maxi-K + channel in patients with OSA after treatment with CPAP
Time frame: 3 months
Primary Outcome Measure: Look at the difference in OSA and control subjects between the parameters that measure blood pressure in AMBP, the reactive hyperemia test for ischemia flowmetry technique and the expression levels of ß1 subunit of the Maxi-K + channel in peripheral blood leukocytes. In OSA group patients after three months of correct treatment with CPAP, the goal is to find: * Improvement in blood pressure parameters (ambulatory blood pressure). * Improved parameters expressing vascular endothelial function at subclinical level (recorded by laser-Doppler flowmetry). * Improvement in levels of β1 subunit expression of Maxi-K + channel in peripheral blood leukocytes (basic).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jun 2013.
- Derived from this study: PubMed 31216297Caballero-Eraso C, Munoz-Hernandez R, Asensio Cruz MI, Moreno Luna R, Carmona Bernal C, Lopez-Campos JL, Stiefel P, Sanchez Armengol A. Relationship between the endothelial dysfunction and the expression of the beta1-subunit of BK channels in a non-hypertensive sleep apnea group. PLoS One. 2019 Jun 19;14(6):e0217138. doi: 10.1371/journal.pone.0217138. eCollection 2019.
Related trials for Obstructive Sleep Apnea
RecruitingObservational study
Development and Validation of a Multimodal Deep Learning Model Using Peripheral Oxygen Saturation and Ballistocardiography Signals for Predicting Apnea-Hypopnea Index in Obstructive Sleep Apnea
Obstructive Sleep Apnea
RecruitingPhase 3
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)
Apnea, Sleep Disorders
Not yet recruitingPhase 2
Supplemental Oxygen for Sleep-Disordered Breathing in Adults With Chronic Opioid Use.
Sleep-disordered Breathing, Chronic Opioid Use
Recruiting
Nightly Wearable Monitoring During Home-Based Submental Electrical Stimulation for Obstructive Sleep Apnea
Obstructive Sleep Apnea
RecruitingPhase 1/2
DRonabinol Treatment of OSA
Obstructive Sleep Apnea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Angeles Sánchez Armengol, Md PhD principal investigator
Hospitales Universitarios Virgen del Rocío
Questions about this trial
What is this clinical trial studying?
An observational study of Obstructive Sleep Apnea, run by Angeles Sanchez Armengol.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Jun 2013. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Improvement in blood pressure parameters, in vascular endothelial function and in levels of β1 subunit expression of Maxi-K + channel in patients with OSA after treatment with CPAP (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01791270, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jun 2013.